Astrazeneca PLC ORD SHS $0.25
Astrazeneca PLC ORD SHS $0.25/ GB0009895292 /
AZN
|
2025. 01. 10. 13:47:07
|
Vált.
-80,0000
|
Forgalom (db) |
Vétel13:47:13 |
Eladás13:47:12 |
Piaci kapitalizáció |
Osztalékh. |
P/E Ráta |
|
10 908,0000GBX
|
-0,73%
|
253 570
Forgalom(GBP): 27,83 mill. |
10 906,0000Vétel (db): 335 |
10 910,0000Eladás (db): 451 |
166,45 mrd.GBP |
- |
- |
Cégbemutató
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Igazgatóság & Felügyelőbizottság
| CEO |
| Pascal Soriot |
| Igazgatóság |
| Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
| Felügyelőbizottság |
| Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg, Anna Manz |